Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Cediranib + Carboplatin + Paclitaxel lung cancer no benefit detail...
ERBB2 mutant Neratinib lung cancer sensitive detail...
Unknown unknown Nintedanib lung cancer not applicable detail...
KRAS G12D BEZ235 lung cancer no benefit detail...
KRAS G12D Selumetinib + BEZ235 lung cancer sensitive detail...
EML4-ALK ALK G1202R Lorlatinib lung cancer conflicting detail...
FGFR1 amp Brivanib lung cancer no benefit detail...
Unknown unknown Cediranib + Gefitinib lung cancer not applicable detail...
KRAS G12D SH-1242 lung cancer sensitive detail...
Unknown unknown SNG12 lung cancer not applicable detail...
Unknown unknown TAK-960 lung cancer not applicable detail...
KRAS G12D STK11 inact mut Sapanisertib lung cancer sensitive detail...
STK11 loss unspecified PD-1 antibody lung cancer resistant detail...
EML4-ALK SRC pos Ropotrectinib lung cancer sensitive detail...
EML4-ALK SRC pos Crizotinib lung cancer resistant detail...
Unknown unknown HD105 lung cancer not applicable detail...
Unknown unknown AZD7762 + VX-970 lung cancer not applicable detail...
MET over exp Crizotinib + Rucaparib lung cancer sensitive detail...
KRAS G12S Trametinib lung cancer decreased response detail...
KRAS G12S Refametinib lung cancer decreased response detail...
KRAS G12S PD-0325901 lung cancer decreased response detail...
Unknown unknown ABTL0812 lung cancer not applicable detail...
FGFR1 amp AZD4547 lung cancer sensitive detail...
FGFR1 wild-type AZD4547 lung cancer decreased response detail...
ERBB2 Y772_A775dup Afatinib lung cancer sensitive detail...
ERBB2 G776delinsVC Afatinib lung cancer sensitive detail...
ERBB2 G776delinsLC Afatinib lung cancer sensitive detail...
ERBB2 G778_P780dup Afatinib lung cancer sensitive detail...
ERBB2 Y772_A775dup Gefitinib lung cancer no benefit detail...
ERBB2 G776delinsVC Gefitinib lung cancer no benefit detail...
ERBB2 G776delinsLC Gefitinib lung cancer no benefit detail...
ERBB2 G778_P780dup Gefitinib lung cancer no benefit detail...
ERBB2 V659E Gefitinib lung cancer no benefit detail...
ERBB2 G660D Gefitinib lung cancer no benefit detail...
ERBB2 V659E Afatinib lung cancer sensitive detail...
ERBB2 G660D Afatinib lung cancer sensitive detail...
NOTCH1 positive LY3039478 lung cancer sensitive detail...
ERBB2 T798I Lapatinib lung cancer resistant detail...
KRAS G12C SCH772984 + Trametinib lung cancer sensitive detail...
BRAF dec exp KRAS G12C Trametinib lung cancer sensitive detail...
FGFR1 dec exp KRAS mut Trametinib lung cancer sensitive detail...
FGFR2 dec exp KRAS mut Trametinib lung cancer no benefit detail...
FGFR3 dec exp KRAS mut Trametinib lung cancer no benefit detail...
FGFR1 dec exp KRAS wild-type Trametinib lung cancer no benefit detail...
KRAS mutant Ponatinib + Trametinib lung cancer sensitive detail...
KRAS wild-type Ponatinib + Trametinib lung cancer decreased response detail...
KRAS mutant AZD4547 + Trametinib lung cancer sensitive detail...
KRAS mutant BGJ398 + Trametinib lung cancer sensitive detail...
KRAS mutant Crizotinib + Trametinib lung cancer sensitive detail...
KRAS mutant Gefitinib + Trametinib lung cancer no benefit detail...
KRAS mutant Afatinib + Trametinib lung cancer no benefit detail...
Unknown unknown CBP501 + Cisplatin lung cancer not applicable detail...
MET amp SAR125844 lung cancer sensitive detail...
KRAS G12A MET amp SAR125844 lung cancer resistant detail...
KRAS G12S APS-2-79 + Trametinib lung cancer sensitive detail...
KRAS G12S APS-2-79 + Binimetinib lung cancer sensitive detail...
KRAS G12S APS-2-79 + PD-0325901 lung cancer sensitive detail...
KRAS G12S APS-2-79 + Selumetinib lung cancer sensitive detail...
TP53 wild-type AMG 232 lung cancer sensitive detail...
TP53 loss AMG 232 lung cancer resistant detail...
TP53 wild-type AMG 232 + Radiotherapy lung cancer sensitive detail...
TP53 loss AMG 232 + Radiotherapy lung cancer resistant detail...
Unknown unknown Apatinib lung cancer not applicable detail...
KRAS G12S rigosertib lung cancer sensitive detail...
MET amp AMG 337 lung cancer sensitive detail...
KRAS G12A MET amp AMG 337 lung cancer resistant detail...
Unknown unknown PU-H71 lung cancer not applicable detail...
KRAS act mut Dinaciclib lung cancer predicted - sensitive detail...
Unknown unknown Dinaciclib + Paclitaxel lung cancer not applicable detail...
RET rearrange Cabozantinib lung cancer sensitive detail...
Unknown unknown ABT-737 + Perifosine lung cancer not applicable detail...
KRAS G12V Aurora Kinase Inhibitor II lung cancer sensitive detail...
Unknown unknown Metformin lung cancer not applicable detail...
KRAS mutant PF3644022 + PF-477736 lung cancer predicted - sensitive detail...
CDKN2A del PF3644022 + PF-477736 lung cancer predicted - sensitive detail...
Unknown unknown CT16 lung cancer not applicable detail...
EML4-ALK X-376 lung cancer sensitive detail...
Unknown unknown TC-A2317 lung cancer not applicable detail...
MET amp Golvatinib lung cancer sensitive detail...
KRAS G12V 7RH + LY411575 lung cancer sensitive detail...
KRAS G12V TP53 del 7RH lung cancer resistant detail...
KRAS G12V TP53 del 7RH + LY411575 lung cancer sensitive detail...
Unknown unknown AZ628 + Trametinib lung cancer not applicable detail...
FGFR1 amp Erdafitinib lung cancer predicted - sensitive detail...
FGFR1 amp KRAS G12V Erdafitinib lung cancer resistant detail...
FGFR1 amp KRAS amp Erdafitinib lung cancer resistant detail...
KRAS G12C AZD4785 lung cancer sensitive detail...
KRAS mutant DT-061 lung cancer predicted - sensitive detail...
FGFR1 amp GSK3052230 lung cancer sensitive detail...
MET amp MET del exon14 Glesatinib lung cancer sensitive detail...
FGFR1 amp MET dec exp AZD4547 lung cancer sensitive detail...
FGFR1 amp MET pos AZD4547 lung cancer resistant detail...
FGFR1 amp MET dec exp Rogaratinib lung cancer sensitive detail...
FGFR1 amp MET pos Regorafenib lung cancer resistant detail...
FGFR1 amp MET amp AZD4547 lung cancer resistant detail...
FGFR1 amp MET over exp Regorafenib lung cancer resistant detail...
FGFR1 amp MET amp AZD4547 + Crizotinib lung cancer sensitive detail...
FGFR1 amp MET over exp Crizotinib + Regorafenib lung cancer sensitive detail...
MET amp Glesatinib lung cancer sensitive detail...
MET del exon14 Glesatinib lung cancer sensitive detail...
MET over exp SYM015 lung cancer sensitive detail...
MET del exon14 SYM015 lung cancer sensitive detail...
MET del exon14 Emibetuzumab lung cancer decreased response detail...
BRAF V600E Ulixertinib lung cancer sensitive detail...
BRAF L597Q Ulixertinib lung cancer sensitive detail...
U2AF1 S34F H3B-8800 lung cancer sensitive detail...
KRAS G12D AR-mTOR-26 lung cancer predicted - sensitive detail...
Unknown unknown Triolimus lung cancer not applicable detail...
CTNNB1 T41A NTRC 0066-0 lung cancer predicted - sensitive detail...
CTNNB1 T41A Mps-BAY2b lung cancer predicted - sensitive detail...
CTNNB1 T41A NMS-P715 lung cancer predicted - sensitive detail...
CTNNB1 T41A BAY1161909 lung cancer predicted - sensitive detail...
CTNNB1 T41A BAY1217389 lung cancer predicted - sensitive detail...
CTNNB1 T41A Mps1-IN-1 lung cancer predicted - sensitive detail...
CTNNB1 T41A MPI-0479605 lung cancer predicted - sensitive detail...
Unknown unknown Camrelizumab lung cancer not applicable detail...
NRAS Q61K RAF709 lung cancer sensitive detail...
ATM positive AZD1390 lung cancer sensitive detail...
ERBB2 Y772_A775dup Poziotinib lung cancer sensitive detail...
AKT1 S266L FGFR1 amp PD173074 lung cancer predicted - resistant detail...
FGFR1 amp PD173074 lung cancer sensitive detail...
AKT1 S266L FGFR1 amp GSK2141795 lung cancer predicted - sensitive detail...
BRAF G469A RMC-4550 lung cancer resistant detail...
BRAF G466V RMC-4550 lung cancer predicted - sensitive detail...
KRAS G12A RMC-4550 lung cancer sensitive detail...
KRAS G12C RMC-4550 lung cancer sensitive detail...
KRAS Q61K RMC-4550 lung cancer predicted - resistant detail...
KRAS Q61H RMC-4550 lung cancer predicted - resistant detail...
KRAS G13D RMC-4550 lung cancer predicted - resistant detail...
KRAS G12V RMC-4550 lung cancer predicted - sensitive detail...
KRAS G12S RMC-4550 lung cancer predicted - resistant detail...
KRAS G12D RMC-4550 lung cancer predicted - resistant detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01014598 Phase I Cisplatin Cisplatin in Treating Patients With Lung Cancer Active, not recruiting
NCT01218867 Phase Ib/II Anti-VEGFR2 CAR CD8 lymphocytes Cyclophosphamide Fludarabine Aldesleukin Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes Completed
NCT01366144 Phase I Paclitaxel Veliparib Carboplatin Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Suspended
NCT01386580 Phase Ib/II 2B3-101 2B3-101 + Trastuzumab An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. Completed
NCT01470209 Phase I BKM120 + Everolimus A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies Completed
NCT01859026 Phase I MEK162 + Erlotinib A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation Recruiting
NCT01935336 Phase II Ponatinib Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers Active, not recruiting
NCT01999985 Phase I Dasatinib + Afatinib Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) Active, not recruiting
NCT02047747 Phase II Dacomitinib A Phase II Study of Dacomitinib in Progressive Brain Metastases Terminated
NCT02155465 Phase Ib/II Ruxolitinib + Erlotinib Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib Completed
NCT02241369 Phase I INO-3106 + INO-9012 Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies Completed
NCT02310464 Phase I OBI-821 + OBI-833 Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects Recruiting
NCT02429843 Phase I Paclitaxel + Carboplatin Bevacizumab Carotuximab A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer Active, not recruiting
NCT02538627 Phase I Seribantumab MM-151 Phase 1 Combination Study of MM-151 and MM-121 Terminated
NCT02675829 Phase II trastuzumab emtansine Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers Active, not recruiting
NCT03188965 Phase I BAY1895344 First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas Recruiting
NCT03199586 Phase I NP-G2-044 Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma) Recruiting
NCT03373760 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer Recruiting
NCT03477162 Phase 0 Metformin Metformin Pharmacology in Human Cancers: A Proof of Principle Study Recruiting
NCT03597009 Phase Ib/II Talimogene laherparepvec + Nivolumab A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion Not yet recruiting
NCT03719768 Phase I Avelumab Avelumab With Radiotherapy in Patients With Leptomeningeal Disease Recruiting